Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 11/20 | 0.55 |
| ▸ | NR1H3 | Q13133 | 11/20 | 0.55 |
| ▸ | RXRA | P19793 | 5/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3471463 | 0.91 | NR1H2 (0.49) | NR1H2NR1H3RXRAKIF18APIK3CA | |
| SCHEMBL3473490 | 0.87 | NR1H2 (0.62) | NR1H2NR1H3RXRAPTGS2HSD11B1 | |
| SCHEMBL3473202 | 0.85 | NR1H2 (0.54) | NR1H2NR1H3RXRAPTGS2HSD11B1 | |
| SCHEMBL3474840 | 0.82 | NR1H2 (0.61) | NR1H2NR1H3RXRAPIK3CAHSD11B1 | |
| SCHEMBL3475017 | 0.80 | NR1H2 (0.55) | NR1H2NR1H3RXRAPIK3CA | |
| SCHEMBL3471651 | 0.80 | NR1H2 (0.78) | NR1H2NR1H3RXRAPTGS2PIK3CA | |
| SCHEMBL3475326 | 0.79 | NR1H2 (0.60) | NR1H2NR1H3RXRAPIK3CAHSD11B1 | |
| SCHEMBL3475904 | 0.79 | NR1H2 (0.55) | NR1H2NR1H3RXRAPIK3CA | |
| SCHEMBL3471229 | 0.77 | NR1H2 (0.77) | NR1H2NR1H3RXRAPTGS2PIK3CA | |
| SCHEMBL3473357 | 0.76 | NR1H2 (0.67) | NR1H2NR1H3RXRAPTGS2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885RXRA 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.